Iambic Therapeutics · 公司档案

公开已核验进展

1. Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND

   Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据

   据 Iambic 官方公告，已提交 IAM217 的 IND 申请。提交申请不等于监管批准，也不代表临床疗效已获证实。

   Iambic Therapeutics

   核查事件证据 →

2. Iambic 与 AbbVie 宣布 AI 药物发现合作

   Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据

   据双方在 Iambic 官网发布的公告，将利用 Iambic 的 AI 平台合作开展药物发现，提高候选药物识别效率。属于公司宣布的合作，未独立验证研发成效。

   艾伯维 · Iambic Therapeutics

   核查事件证据 →

3. Iambic 与拜耳合作推进 AI 小分子发现

   Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据

   据 Iambic 官方公告，拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现；尚非临床疗效结论。

   拜耳制药 · Iambic Therapeutics

   核查事件证据 →

合作、许可与并购时间线

1. Iambic 与 AbbVie 宣布 AI 药物发现合作

   Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据

   据双方在 Iambic 官网发布的公告，将利用 Iambic 的 AI 平台合作开展药物发现，提高候选药物识别效率。属于公司宣布的合作，未独立验证研发成效。

   艾伯维 · Iambic Therapeutics

   核查事件证据 →

2. Iambic 与拜耳合作推进 AI 小分子发现

   Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据

   据 Iambic 官方公告，拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现；尚非临床疗效结论。

   拜耳制药 · Iambic Therapeutics

   核查事件证据 →

以上来自最新 3 条已核验进展。合作事件成立与模型效果、实验结果或临床进度分别需要证据。

公开原文线索

• Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate

  Iambic official newsroom · 行业原文收录 · 来源发布：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:58 GMT+0000 (Coordinated Universal Time)

  In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intr

  原始出处

• AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

  Iambic official newsroom · 行业原文收录 · 来源发布：Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:23 GMT+0000 (Coordinated Universal Time)

  − Multi-year partnership applies Iambic’s AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology − Companies to pursue programs with both first-in-class and best-in-class potential

  原始出处

• Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development

  Iambic official newsroom · 行业原文收录 · 来源发布：Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:09 GMT+0000 (Coordinated Universal Time)

  Enchant v3 is the next generation of Iambic’s multimodal transformer model, trained using 41 billion parameters on more than 6,000 molecular properties across 16 biomedical data modalities Enchant v3 ingests diverse data

  原始出处

• Bayer and Iambic collaborate to advance drug discovery with AI

  Iambic official newsroom · 行业原文收录 · 来源发布：Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)

  Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’

  原始出处

• Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

  Iambic official newsroom · 行业原文收录 · 来源发布：Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)

  San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz

  原始出处

已验证的官方与订阅来源

• Iambic official newsroom · 采集已启用 · 最近成功 Thu Oct 08 2026 15:08:09 GMT+0000 (Coordinated Universal Time)

来源验证与持续采集分别显示；原文收录不自动成为已核验事件。